José
Palacios Calvo
Profesor/a Titular Universidad
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (1)
2012
-
Classical markers like ER and Ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: Results from the GEICAM/2002-01 phase II study
Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 430-436